Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.35
+1.43 (0.69%)
AAPL  265.52
-7.43 (-2.72%)
AMD  198.95
-4.73 (-2.32%)
BAC  49.56
-2.74 (-5.24%)
GOOG  306.61
-0.54 (-0.18%)
META  638.62
-18.39 (-2.80%)
MSFT  393.44
-8.28 (-2.06%)
NVDA  179.21
-5.68 (-3.07%)
ORCL  142.44
-7.87 (-5.24%)
TSLA  399.32
-9.25 (-2.27%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.